According to scientific advances over the last 20 years, aging and the aging process is the result of nutritional, hormone, and peptide deficiencies that increase over time. Deficiencies often increase due to a weakening of our endocrine glands. This weakening causes the declining function of our tissues and ultimately leads to a lower quality of life. We often notice weakening and declining tissues by the increasing lining and sagging of our facial tissues. These symptoms are indicative of a shortened lifespan.
To counter these effects, and especially to counter memory loss and senility, we should engage in frequent physical exercise and adopt a well-balanced supplement program as described below.
Aging is not a disease. Thus, prevention is possible.
An increasing body of scientific publications suggests that seven hormone therapies may effectively help restore memory and slow dementia. In the case of Alzheimer’s, the first approach is to improve the behavior and well-being of patients with various amino acid and hormone therapies. Among these, oxytocin (OxyMax) supplementation plays a central role; the treatment is effective in helping the patient be more sociable and willing to cooperate. Oxytocin calms aggressive outbursts that often arise in patients with senility.
Second, patients with apathetic depression may be helped with DHEA (DHEA-MAX) therapy (2). DHEA supplements have been shown to help with memory loss in mice and humans. DHEA enhances memory by improving REM sleep. Indeed, Alzheimer’s patients have low levels of DHEA.
A third therapy that results in improved behavior is melatonin. When taken at bedtime, melatonin prevents sleep disruptions and “sun-downing” (agitation occurring in the evening or at sundown), which are characteristics of Alzheimer’s-type senility. Melatonin protects against Alzheimer’s by reducing the formation of intracellular neurofibrillary tangles and the extracellular accumulation of amyloid-beta, two features of Alzheimer’s. Melatonin has also been shown to sharply decrease free radical damage and apoptosis of hippocampal neurons and to protect rodent brains against aluminum toxicity discovered by Dr. Johan Björksten in1963. In a personal conversation I had with him, Dr. Björksten told me he discovered that aluminum from cooking utensils may induce an Alzheimer-like disease in rodents and therefore perhaps even in humans. Low serum melatonin levels have been positively correlated with low scores on the mini-mental state examination. As with DHEA, melatonin is often found to be very low in Alzheimer’s patients.
Fourth, another efficient treatment therapy is called IGF-1 (insulin-like factor 1). Insulin levels are positively correlated with longevity in 18 studies. IGF-1 can be administered alone or combined with growth hormone therapy (SermMax and ReleasingMax), which has shown positive effects on cognition, although this effect is reduced in older adults. Indeed, in older adults, IGF-1 therapy may reverse brain atrophy. Studies have shown that higher serum IGF-1 levels are associated with greater brain volume and better cognition in older adults along with a reduced risk of Alzheimer’s. Studies on mice have shown that subcutaneous injections could be replaced by intranasal administration of IGF-1. These forms of administration are less invasive than injections. IGF-1 not only increases neurogenesis in the brain and especially in the hippocampus but also increases glucose utilization in the brain and can strongly reduce amyloid beta neurotoxicity. It also protects neurons of the hippocampus in human cell culture.
A fifth memory-enhancing therapy for women is the use of female hormones, namely estrogens. This type of therapy should be used for hormone balance, especially in the case of bioidentical Progesterone (Progesterone-Max). Alzheimer’s generally occurs after menopause, a period characterized by severe female hormone deficiency. Women with Alzheimer’s have significantly lower serum and cerebrospinal fluid levels than age-matched controls without cognitive impairment. Depending on the study, the risk of Alzheimer’s is described as three to eight times higher in postmenopausal women who never used estrogens compared to similar women who are taking estrogens. Several studies have shown that transdermal (and in some cases, orally administered) bioidentical estrogen therapy improves cognition in Alzheimer’s patients.
Testosterone therapy is ranked as the fourth leading therapy for cognitive function in men and the sixth most effective in women who are already receiving HRT (hormone replacement therapy). Men with Alzheimer’s often have lower serum testosterone, and low serum testosterone is a significant risk factor for Alzheimer’s. Testosterone improves memory in Alzheimer’s patients. Testosterone increases brain blood low, thickens the myelin sheath, increases the number of dendrites and synaptic connections, and reduces amyloid-beta peptide production and neurotoxicity.
Vasopressin therapy (VasoMax) is a hormone therapy that can effectively improve both short- and long-term memory. Vasopressin levels have been reported as deficient in the cerebrospinal fluid of patients with Alzheimer’s and postmortem in the brain cortex for the same population. Patients with overt vasopressin deficiency suffer from significant short- and long-term memory losses. The younger the patient is, the greater the potential improvement in memory. Homeopathic vasopressin (VasoMax) often performs better than its synthetic derivative (desmopressin). It should be consumed upon awakening or in the middle of the day.
In conclusion, once senility is diagnosed, seven therapies associated with one another may help to oppose its progression and may even help to reactivate memory and cognition during aging.